Industry Issues: Dataset Preparation for Time to Event Analysis Davis Gates Schering Plough Research Institute.

Slides:



Advertisements
Similar presentations
Appraisal of an RCT using a critical appraisal checklist
Advertisements

Labeling claims for patient- reported outcomes (A regulatory perspective) FDA/Industry Workshop Washington, DC September 16, 2005 Lisa A. Kammerman, Ph.D.
The Application of Propensity Score Analysis to Non-randomized Medical Device Clinical Studies: A Regulatory Perspective Lilly Yue, Ph.D.* CDRH, FDA,
1 TennCare Diabetes Program Evaluation Presentation to AcademyHealth Kenton Johnston, MPH, MS, MA June 4, 2007 An Individually-Matched Control Group Evaluation.
Panel Discussion 1 George Williams Amgen. Barbara Tilley - Sample Size Estimation… Key point – considering both short term benefit of symptomatic treatment.
Study Size Planning for Observational Comparative Effectiveness Research Prepared for: Agency for Healthcare Research and Quality (AHRQ)
If we use a logistic model, we do not have the problem of suggesting risks greater than 1 or less than 0 for some values of X: E[1{outcome = 1} ] = exp(a+bX)/
Controlling for Time Dependent Confounding Using Marginal Structural Models in the Case of a Continuous Treatment O Wang 1, T McMullan 2 1 Amgen, Thousand.
1 QOL in oncology clinical trials: Now that we have the data what do we do?
ATLAS Steering Committee: 24 September 2005 Steering Committee meeting, 24 th September 2005 University of Oxford Examination Schools.
Basic Design Consideration. Previous Lecture Definition of a clinical trial The drug development process How different aspects of the effects of a drug.
Statistical Issues in Contraceptive Trials
Journal Club Alcohol, Other Drugs, and Health: Current Evidence January–February 2009.
Common Problems in Writing Statistical Plan of Clinical Trial Protocol Liying XU CCTER CUHK.
BIOST 536 Lecture 3 1 Lecture 3 – Overview of study designs Prospective/retrospective  Prospective cohort study: Subjects followed; data collection in.
Sample Size Determination Ziad Taib March 7, 2014.
Part 3 of 3 By: Danielle Davidov, PhD & Steve Davis, MSW, MPA INTRODUCTION TO RESEARCH: SAMPLING & DESIGN.
Chronic diseases 1.Chronic diseases have long and variable preclinical phases. 2.The preclinical phase is that portion of the disease natural history during.
Analysis of Complex Survey Data
INCLUSION/EXCLUSION CRITERIA 1. The following are considerations when defining the cardiac arrest trial patient population (i.e., the inclusion/exclusion.
As noted by Gary H. Lyman (JCO, 2012) “CER is an important framework for systematically identifying and summarizing the totality of evidence on the effectiveness,
Marshall University School of Medicine Department of Biochemistry and Microbiology BMS 617 Lecture 10: Survival Curves Marshall University Genomics Core.
Estimating cancer survival and clinical outcome based on genetic tumor progression scores Jörg Rahnenführer 1,*, Niko Beerenwinkel 1,, Wolfgang A. Schulz.
Clinical Trials. What is a clinical trial? Clinical trials are research studies involving people Used to find better ways to prevent, detect, and treat.
Overview of the Clinical Trial & Protocol Jane Fendl March 31, 2010
Intervention Studies Principles of Epidemiology Lecture 10 Dona Schneider, PhD, MPH, FACE.
Lecture 8 Objective 20. Describe the elements of design of observational studies: case reports/series.
Gil Harari Statistical considerations in clinical trials
Lecture 16 (Oct 28, 2004)1 Lecture 16: Introduction to the randomized trial Introduction to intervention studies The research question: Efficacy vs effectiveness.
Study design P.Olliaro Nov04. Study designs: observational vs. experimental studies What happened?  Case-control study What’s happening?  Cross-sectional.
Experimental Design making causal inferences Richard Lambert, Ph.D.
Delivering Robust Outcomes from Multinational Clinical Trials: Principles and Strategies Andreas Sashegyi, PhD Eli Lilly and Company.
Consumer behavior studies1 CONSUMER BEHAVIOR STUDIES STATISTICAL ISSUES Ralph B. D’Agostino, Sr. Boston University Harvard Clinical Research Institute.
Successful Concepts Study Rationale Literature Review Study Design Rationale for Intervention Eligibility Criteria Endpoint Measurement Tools.
Introduction to Survival Analysis Utah State University January 28, 2008 Bill Welbourn.
1 Presented by Eugene Laska, Ph.D. at the Arthritis Advisory Committee meeting 07/30/02.
What is a non-inferiority trial, and what particular challenges do such trials present? Andrew Nunn MRC Clinical Trials Unit 20th February 2012.
Lecture 9: Analysis of intervention studies Randomized trial - categorical outcome Measures of risk: –incidence rate of an adverse event (death, etc) It.
Federal Institute for Drugs and Medical Devices The BfArM is a Federal Institute within the portfolio of the Federal Ministry of Health (BMG) The use of.
Biostatistics Case Studies 2006 Peter D. Christenson Biostatistician Session 4: An Alternative to Last-Observation-Carried-Forward:
1 Lecture 6: Descriptive follow-up studies Natural history of disease and prognosis Survival analysis: Kaplan-Meier survival curves Cox proportional hazards.
1 Study Design Issues and Considerations in HUS Trials Yan Wang, Ph.D. Statistical Reviewer Division of Biometrics IV OB/OTS/CDER/FDA April 12, 2007.
Sifting through the evidence Sarah Fradsham. Types of Evidence Primary Literature Observational studies Case Report Case Series Case Control Study Cohort.
Satistics 2621 Statistics 262: Intermediate Biostatistics Jonathan Taylor and Kristin Cobb April 20, 2004: Introduction to Survival Analysis.
1 Efficacy of Acamprosate: Clinical Issues Celia Jaffe Winchell, M.D. Medical Team Leader Addiction Drug Products.
Biostatistics Case Studies 2006 Peter D. Christenson Biostatistician Session 3: An Alternative to Last-Observation-Carried-Forward:
Session 6: Other Analysis Issues In this session, we consider various analysis issues that occur in practice: Incomplete Data: –Subjects drop-out, do not.
THE ROLE OF SUBGROUPS IN CLINICAL TRIALS Ralph B. D’Agostino, Sr., PhD Boston University September 13, 2005.
1 Pulminiq™ Cyclosporine Inhalation Solution Pulmonary Drug Advisory Committee Meeting June 6, 2005 Statistical Evaluation Statistical Evaluation Jyoti.
1 Chapter 6 SAMPLE SIZE ISSUES Ref: Lachin, Controlled Clinical Trials 2:93-113, 1981.
Approaches to quantitative data analysis Lara Traeger, PhD Methods in Supportive Oncology Research.
Study Design: Making research pretty Adam P. Sima, PhD July 13, 2016
April 18 Intro to survival analysis Le 11.1 – 11.2
The Importance of Adequately Powered Studies
Anastasiia Raievska (Veramed)
Clinicaltrials.gov Update
CLINICAL PROTOCOL DEVELOPMENT
Donald E. Cutlip, MD Beth Israel Deaconess Medical Center
The Diabetic Retinopathy Clinical Research Network
ASPIRE Workshop 5: Application of Biostatistics
ASPIRE Workshop 5: Application of Biostatistics
Common Problems in Writing Statistical Plan of Clinical Trial Protocol
Annals of Internal Medicine • Vol. 167 No. 12 • 19 December 2017
1 Verstovsek S et al. Proc ASH 2012;Abstract Cervantes F et al.
Handling Missing Not at Random Data for Safety Endpoint in the Multiple Dose Titration Clinical Pharmacology Trial Li Fan*, Tian Zhao, Patrick Larson Merck.
ASPIRE Workshop 5: Application of Biostatistics
Use of Piecewise Weighted Log-Rank Test for Trials with Delayed Effect
Björn Bornkamp, Georgina Bermann
Kaplan-Meier survival curves and the log rank test
2019 Joint Statistical Meetings at Denver
Presentation transcript:

Industry Issues: Dataset Preparation for Time to Event Analysis Davis Gates Schering Plough Research Institute

Not all Clinical Trials are Designed for Time to Event Analysis However, time to events are common secondary analyses in many clinical trials, later requiring PRIMARY attention. These comments address those types of studies.

Obstacles to optimal Time-to-event Analysis Secondary Parameter: study not powered for this analysis Secondary Parameter: study not powered for this analysis Low Incidence of Events: resulting in poor or impossible estimate of time-to-event by treatment Low Incidence of Events: resulting in poor or impossible estimate of time-to-event by treatment Determination of Event: During vs. after the treatment period Determination of Event: During vs. after the treatment period Censoring Issues: Rate very high or poorly defined Censoring Issues: Rate very high or poorly defined Bias due to Per Patient Duration of Treatment: another term meaning early drop outs Bias due to Per Patient Duration of Treatment: another term meaning early drop outs

Secondary Parameter Study may be powered for a defined delta of a continuous outcome variable. Study may be powered for a defined delta of a continuous outcome variable. Time-to-event among a long list of secondary analyses. Time-to-event among a long list of secondary analyses. Cannot rely on statistical inference for final conclusions (PROC LIFETEST), therefore, a clinically meaningful difference should be assessed in lieu of a p-value. Cannot rely on statistical inference for final conclusions (PROC LIFETEST), therefore, a clinically meaningful difference should be assessed in lieu of a p-value.

Low Incidence of Events Time to event analysis may not be feasible for a population of patients who experience a low proportion of events. Time to event analysis may not be feasible for a population of patients who experience a low proportion of events. How many times have we seen non estimable MEDIAN time to events? How many times have we seen non estimable MEDIAN time to events? May have to break down to a categorical analysis (EVENT=YES or NO), losing the time to event element. (We should have enrolled more sickly subjects) May have to break down to a categorical analysis (EVENT=YES or NO), losing the time to event element. (We should have enrolled more sickly subjects)

Determination of Event Even though the event itself may be clearly defined, the probability of event vs. relation to treatment may not be so clear. (are all events treated equally?) Even though the event itself may be clearly defined, the probability of event vs. relation to treatment may not be so clear. (are all events treated equally?) The evaluation of event can differ in two contrasting treatment methods such as daily topical vs. monthly intravenous. The evaluation of event can differ in two contrasting treatment methods such as daily topical vs. monthly intravenous. Generally analyze ALL data, regardless of temporal relationship with treatment, but why not define the drug relation interval, and use this to enforce follow-up? Generally analyze ALL data, regardless of temporal relationship with treatment, but why not define the drug relation interval, and use this to enforce follow-up?

Simple Case – Daily Dosing Regimen Daily/periodic Inhaled/Topical Drug with minimal /no Blood Level Impact: Treatment Period: Last Day of Dose + Delta Last Day of Dose + Delta Delta = period of time no shorter than treatment duration claim, but can include a wash-out period treatment duration claim, but can include a wash-out period

Treatment Period for Drugs with Long Half-Life/Infrequent Dosing Regimen Long-acting Drug such as a monthly IV or single dose with long Blood level half life… Treatment Period can last through: Last Dose Date +N*t 1/2 N = number of half lives (t 1/2 ), each of which can be of several days or weeks in length (N=5 generally determines drug wash-out) This criteria can require a considerable amount of follow-up.

Censoring Issues General Time-to-event methodology, even though censors are handled, were not optimally designed for data with heavy censoring. Large scale clinical trials can have a high proportion of censored subjects (20% or more). This places an emphasis in improvements in follow-up for all subjects, even those discontinued from the trial. This is related to the issue of low proportion of events, which leave the potential for high proportion of censors.

Patient Duration of Treatment Is time-to-event (or survival) analysis the ultimate missing data analysis? Certainly not, subjects drop out for many reasons, related or not related to treatment or covariates. Is time-to-event (or survival) analysis the ultimate missing data analysis? Certainly not, subjects drop out for many reasons, related or not related to treatment or covariates. Calculation of event rates can be biased by early drop-outs. Calculation of event rates can be biased by early drop-outs.

Duration of Treatment (Cont…) Early Drop Outs: it is in our interest to follow up subjects, give them a chance to report an event – even if discontinued from a trial, to reduce this bias. Early Drop Outs: it is in our interest to follow up subjects, give them a chance to report an event – even if discontinued from a trial, to reduce this bias. In many cases the probability of a subject reporting an event is reduced with an early drop out, producing by treatment event rates biased downward. In many cases the probability of a subject reporting an event is reduced with an early drop out, producing by treatment event rates biased downward.

The Perfect Dataset First Day of Treatment Documented First Day of Treatment Documented Each Event Date Recorded with pre or post dose information for that day Each Event Date Recorded with pre or post dose information for that day Last Day of Treatment Documented Last Day of Treatment Documented Last Visit Day Documented Last Visit Day Documented All Subjects receive follow-up regardless of treatment or discontinuation status (Insure open communication opportunity – at least remotely). All Subjects receive follow-up regardless of treatment or discontinuation status (Insure open communication opportunity – at least remotely). Last contact date Documented Last contact date Documented Last Day of follow-up clearly documented (last contact date is optimal, but may have to settle for last visit date) Last Day of follow-up clearly documented (last contact date is optimal, but may have to settle for last visit date) Censoring and Events to be determined by availability of above data and a pre-specified algorithm. Censoring and Events to be determined by availability of above data and a pre-specified algorithm.